About the Authors
- Mohammad Hojjat-Farsangi
-
* E-mail: mohammad.hojat-farsangi@ki.se
Affiliations Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden, Department of Immunology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
- Fatemeh Ghaemimanesh
-
Affiliation Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
- Amir Hossein Daneshmanesh
-
Affiliation Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
- Ali-Ahmad Bayat
-
Affiliation Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
- Jafar Mahmoudian
-
Affiliation Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
- Mahmood Jeddi-Tehrani
-
Affiliation Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
- Hodjatallah Rabbani
-
Affiliation Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
- Hakan Mellstedt
-
Affiliation Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
Supervised the experiments: MHF HM. Reviewed the manuscript: MHF AAB AHD JM MJT HM. Designed the ROR1 peptides and provided the mAbs for this study: HR. Conceived and designed the experiments: MHF. Performed the experiments: FG AAB AHD JM. Wrote the paper: MHF HM.